Alibaba Health Information Technology Limited (ALI HEALTH) filed its Monthly Return for April 2026, confirming a steady equity structure with no share issuances, cancellations or treasury share movements during the period. Key takeaways are as follows:

• Authorised Capital Unchanged The company’s authorised share capital remained at 20.00 billion ordinary shares with a par value of HKD 0.01, equivalent to HKD 200.00 million. No increase or reduction was recorded.

• Issued Shares Steady at 16.18 Billion Issued ordinary shares closed April at 16.18 billion (16,175,300,965), identical to the March-end balance. The group continues to hold zero treasury shares.

• Public Float Above 25% Threshold Management confirmed compliance with the Hong Kong Stock Exchange’s minimum 25 percent public-float requirement for Main Board issuers.

• Equity Incentives: 140.46 Million Potential New Shares 1. Share Option / Award Schemes – Legacy scheme (adopted 24 Nov 2014) shows 17.20 million options outstanding. – 2024 scheme (adopted 30 Aug 2024) shows 1.70 million options outstanding. – No options were exercised in April, and no funds were raised from option exercises.

2. Restricted Share Units (RSUs) – Seventeen RSU grants approved between 2021 and March 2026 could deliver up to 121.56 million new shares.

Combining outstanding options and RSUs, a total of roughly 140.46 million shares are potentially dilutive, representing about 0.87 percent of ALI HEALTH’s current issued share capital.

No warrants, convertible securities or other equity-linked instruments were reported for the month. The company’s capital structure therefore remains effectively unchanged, with limited dilution risk in the near term and continued adherence to listing-rule requirements.